Boone Memorial Hospital, INC

Boone Memorial Hospital, INC was paid $31.87M by Medicaid between Jan 2018 and Dec 2024, across 212 billing codes. Its largest line is 99285, emergency room visit (most serious) — 9.1% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	76,924	$4.91M
2019	39,662	$2.53M
2020	95,771	$7.31M
2021	93,369	$5.89M
2022	71,460	$3.89M
2023	88,279	$4.26M
2024incomplete	63,409	$3.08M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	9.1%	16,086	12,617	$2.89M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	8.4%	19,447	16,446	$2.69M
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	8.0%	15,796	14,426	$2.54M
80053	Comprehensive metabolic panel	4.8%	32,907	27,146	$1.52M
74177	Computed tomography, abdomen and pelvis; with contrast material	4.5%	2,875	2,573	$1.45M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	3.9%	14,077	12,532	$1.26M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	2.9%	33,217	25,305	$914K
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	2.8%	1,533	1,164	$905K
87631		2.8%	9,488	8,616	$889K
74176	Computed tomography, abdomen and pelvis; without contrast material	2.5%	2,047	1,836	$805K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	2.5%	3,328	2,965	$802K
70450	Computed tomography, head or brain; without contrast material	2.4%	3,658	3,246	$765K

200 more codes

84484		1.9%	13,787	$606K
36415	Collection of venous blood by venipuncture	1.6%	46,152	$511K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	1.6%	7,716	$506K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	1.5%	898	$467K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	1.3%	9,825	$428K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	1.3%	1,491	$423K
88305	Level IV - Surgical pathology, gross and microscopic examination	1.2%	4,157	$368K
81000		1.1%	20,113	$361K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	1.0%	5,166	$331K
80050	General health panel	<1%	3,961	$317K
71275	Computed tomographic angiography, chest, with contrast material	<1%	968	$305K
96375	Therapeutic injection; each additional sequential IV push	<1%	8,197	$296K
83605		<1%	12,905	$293K
94760		<1%	8,018	$292K
96361	Intravenous infusion, hydration; each additional hour	<1%	5,169	$264K
71045	Radiologic examination, chest; single view	<1%	6,873	$239K
71046	Radiologic examination, chest; 2 views	<1%	4,162	$237K
80061	Lipid panel	<1%	6,547	$235K
83880		<1%	4,836	$230K
87040		<1%	6,852	$230K
82550		<1%	8,317	$220K
82150		<1%	7,455	$218K
72125	Computed tomography, cervical spine; without contrast material	<1%	742	$217K
83690		<1%	7,940	$216K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	4,115	$210K
84443	Thyroid stimulating hormone (TSH)	<1%	4,734	$205K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	531	$202K
97014		<1%	4,397	$186K
87086	Culture, bacterial; quantitative colony count, urine	<1%	5,450	$185K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	292	$184K
80305		<1%	3,979	$179K
82553		<1%	6,550	$171K
80048	Basic metabolic panel (calcium, ionized)	<1%	3,828	$168K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	2,754	$160K
71250		<1%	766	$155K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	2,420	$152K
93017		<1%	771	$141K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	2,517	$133K
85610		<1%	8,946	$131K
85651		<1%	9,259	$128K
85730		<1%	8,552	$122K
83036	Hemoglobin; glycosylated (A1C)	<1%	5,097	$115K
73564		<1%	1,064	$111K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	1,905	$110K
87430		<1%	6,044	$109K
74021		<1%	1,530	$106K
87581		<1%	2,613	$102K
87486		<1%	2,611	$102K
81025		<1%	2,521	$101K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	2,409	$89K
72131		<1%	270	$88K
82803		<1%	2,817	$87K
83735		<1%	4,990	$85K
82962		<1%	5,350	$82K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	2,034	$82K
85379		<1%	2,656	$82K
82607		<1%	1,739	$80K
87081		<1%	2,157	$79K
T1015	A visit at a community health center or clinic (one all-in rate)	<1%	1,034	$77K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	607	$74K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	733	$73K
84439		<1%	2,348	$72K
G0378	Hospital observation service, per hour	<1%	610	$71K
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	1,931	$71K
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	730	$68K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	226	$67K
43450		<1%	233	$64K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	277	$61K
93041		<1%	2,852	$48K
74019		<1%	489	$47K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	590	$47K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	2,272	$45K
93971		<1%	146	$41K
73630		<1%	915	$40K
99214	Doctor's office visit, returning patient (more involved)	<1%	2,048	$39K
86140		<1%	1,061	$38K
36600		<1%	2,846	$38K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	353	$37K
73030		<1%	810	$36K
0097U		<1%	193	$36K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	103	$36K
88342		<1%	751	$35K
99213	Doctor's office visit, returning patient (routine)	<1%	1,210	$34K
84703		<1%	880	$33K
97161		<1%	586	$29K
87070		<1%	876	$29K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	539	$28K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	319	$27K
73610		<1%	491	$27K
87075		<1%	533	$26K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,622	$26K
73130		<1%	628	$26K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	1,048	$26K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	431	$25K
87205		<1%	1,111	$24K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	776	$22K
84480		<1%	543	$22K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	763	$22K
87186		<1%	1,166	$22K
72100		<1%	219	$21K
96367		<1%	853	$19K
82140		<1%	782	$18K
80074		<1%	581	$18K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	31	$17K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	33	$16K
99203	Doctor's office visit, new patient (routine)	<1%	642	$16K
84100		<1%	1,238	$16K
82728		<1%	387	$15K
96376		<1%	652	$14K
72110		<1%	192	$14K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	427	$14K
73110		<1%	201	$12K
36000		<1%	1,198	$12K
96368		<1%	246	$11K
86677		<1%	159	$11K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	270	$11K
J2785	Injection, regadenoson, 0.1 mg	<1%	81	$10K
99204	Doctor's office visit, new patient (more involved)	<1%	612	$10K
J2550	Injection, promethazine hcl, up to 50 mg	<1%	231	$9K
73503		<1%	131	$9K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	225	$9K
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	<1%	24	$8K
70486		<1%	33	$8K
93225		<1%	31	$8K
G0283	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care	<1%	113	$8K
94729		<1%	161	$8K
94727		<1%	160	$8K
86481		<1%	106	$7K
84145		<1%	739	$7K
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	<1%	26	$7K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	243	$7K
87632		<1%	192	$6K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	768	$6K
93880		<1%	29	$6K
82043		<1%	167	$5K
87507		<1%	31	$5K
94060		<1%	160	$5K
86780		<1%	131	$5K
93970		<1%	13	$4K
87522	Neg quan hep c or qual rna	<1%	79	$4K
83540		<1%	295	$4K
80320		<1%	251	$4K
97035		<1%	149	$4K
84153		<1%	87	$4K
87077		<1%	456	$3K
51702		<1%	66	$3K
82746		<1%	79	$3K
84550		<1%	126	$3K
82272		<1%	61	$3K
86308		<1%	111	$3K
80355		<1%	116	$3K
74022		<1%	59	$3K
85027		<1%	125	$3K
73090		<1%	39	$3K
86592		<1%	41	$2K
90715		<1%	71	$2K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	82	$2K
76536		<1%	13	$2K
73590		<1%	30	$2K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	32	$2K
80359		<1%	116	$2K
80356		<1%	116	$2K
80362		<1%	116	$2K
80354		<1%	116	$2K
84466		<1%	13	$1K
76641		<1%	17	$1K
80324		<1%	124	$1K
72170		<1%	15	$1K
86038		<1%	25	$1K
86430		<1%	17	$1K
12001		<1%	13	$1K
72072		<1%	15	$988.99
83550		<1%	40	$980.30
77066	Tomosynthesis, mammo	<1%	13	$968.02
29125		<1%	26	$821.02
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	39	$794.90
82565		<1%	58	$672.35
74018		<1%	15	$662.48
81002		<1%	114	$611.32
11102		<1%	31	$587.98
85007		<1%	17	$539.99
97150	Therapeutic procedure(s), group (2 or more individuals)	<1%	95	$506.42
82009		<1%	53	$433.24
G0659	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes	<1%	135	$349.14
99225		<1%	15	$290.87
86769		<1%	13	$278.90
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	98	$183.46
82570		<1%	15	$160.56
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	104	$154.91
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	67	$128.56
G2025	Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only	<1%	12	$112.00
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	57	$58.14
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	28	$52.33
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	<1%	15	$44.86
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	12	$21.01
J2270	Injection, morphine sulfate, up to 10 mg	<1%	21	$13.13
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	24	$6.17
90792	Psychiatric diagnostic evaluation with medical services	0%	20	$0.00
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	0%	46	$0.00
99309	Subsequent nursing facility care, per day, low to moderate complexity	0%	48	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMALCOLM, DOUGLAS (CFO)